目的 探討標(biāo)準(zhǔn)桃金娘油腸溶膠囊聯(lián)合二羥丙茶堿治療慢性喘息性支氣管炎的臨床療效。方法 選取2022年1月—2024年1月山東省立第三醫(yī)院收治的慢性喘息性支氣管炎110例，隨機(jī)分為對照組（55例）和治療組（55例）。對照組口服二羥丙茶堿片，0.2 g/次，3次/d；治療組在對照組的基礎(chǔ)上口服標(biāo)準(zhǔn)桃金娘油腸溶膠囊，1粒/次，2次/d。兩組患者連續(xù)服用藥物15 d。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀好轉(zhuǎn)時間，氣道重塑因子堿性成纖維細(xì)胞生長因子（b-FGF）、血小板衍生生長因子（PDGF-BB）和血管內(nèi)皮生長因子（VEGF）水平，及炎性因子白細(xì)胞介素-13（IL-13）、腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-10（IL-10）和C反應(yīng)蛋白（CRP）水平。結(jié)果 治療后，治療組總有效率為94.55%，明顯高于對照組（81.82%，P＜0.05）。治療后，與對照組比較，治療組體征好轉(zhuǎn)時間均明顯縮短（P＜0.05）。治療后，兩組患者b-FGF、PDGF-BB、VEGF指標(biāo)水平比治療前明顯降低（P＜0.05），且治療后治療組的指標(biāo)水平均顯著低于對照組（P＜0.05）。治療后，兩組患者IL-13、TNF-α、CRP水平比治療前明顯降低，而IL-10明顯升高（P＜0.05），且治療后治療組IL-13、TNF-α、CRP和IL-10水平改善更明顯（P＜0.05）。結(jié)論 標(biāo)準(zhǔn)桃金娘油腸溶膠囊與二羥丙茶堿協(xié)同治療，能較好地糾正慢性喘息性支氣管炎癥狀，進(jìn)而改善支氣管氣道結(jié)構(gòu)的重塑，減輕氣道炎癥反應(yīng)。

Objective To explore the therapeutic effect and Myrtol Standardized Enteric Coated Soft Capsules combined with diprophylline in treatment of chronic asthmatic bronchitis. Methods Patients (110 cases) with chronic asthmatic bronchitis in Shandong Provincial Third Hospital from January 2022 to January 2024 were randomly divided into control (55 cases) and treatment (55 cases) group. Patients in the control group were po administered with Diprophylline Tablets, 0.2 g/time, three times daily. Patients in the treatment group were po administered with Myrtol Standardized Enteric Coated Soft Capsules, 1 grain/time, twice daily. Patients in two groups were treated for 15 d. After treatment, the clinical evaluations were evaluated, the clinical symptom improvement time, the levels of airway remodeling factor indicators b-FGF, PDGF-BB and VEGF, and the levels of inflammatory factor IL-13, TNF-α, CRP and IL-10 in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 94.55%, which was significantly higher than that in the control group (81.82%, P < 0.05). After treatment, compared with the control group, the time for improving physical signs in the treatment group was significantly shortened (P < 0.05). After treatment, the levels of b-FGF, PDGF-BB, and VEGF in two groups were significantly lower than those before treatment (P < 0.05), and the levels of indicators in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of IL-13, TNF-α, and CRP in two groups were significantly lower than before treatment, while IL-10 was significantly increased (P < 0.05). After treatment, the levels of IL-13, TNF-α, CRP and IL-10 were improved more significantly in the treatment group (P < 0.05). Conclusion The synergistic treatment of Myrtol Standardized Enteric Coated Soft Capsules and Diprophylline Tablets can better correct the symptoms of chronic wheezing bronchitis, thereby improving the remodeling of bronchial and airway structure and reducing airway inflammatory reactions.

R974